Pamlico BioPharma pulls in $2.2 mln Series A

Oklahoma City-based Pamlico BioPharma Inc, a developer of fully human monoclonal antibody therapeutics and point-of-care diagnostics, has received $2.2 million in Series A funding. Accele Venture Partners and the Oklahoma Seed Capital Fund led the round.

North AmericaUSBriefs